Business Context and Reporting Period
This Form 8-K is filed by AIT Therapeutics, Inc. (not Beyond Air, Inc.) on August 13, 2018. The report covers corporate governance changes and the announcement of financial results for the quarter ended June 30, 2018, which were issued via a press release on August 14, 2018.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing the financial results for the quarter ended June 30, 2018. However, the text of this 8-K does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The filing explicitly states that the information in the press release is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Material Changes and Corporate Actions
- Board Resignation: David Grossman resigned from the Board of Directors and as Secretary effective August 13, 2018. He cited no disagreement with the Company regarding operations or policies.
- Board Appointment: William P. Forbes, Pharm.D., was appointed to the Board effective August 13, 2018, to fill the vacancy. Dr. Forbes is the CEO of Vivelix Pharmaceuticals, Ltd., and has extensive experience in clinical development and regulatory affairs.
- Equity Plan Adoption: The Board approved the Amended and Restated 2013 Equity Incentive Plan, authorizing up to 1,500,000 shares for issuance. The plan terminates on August 13, 2028.
- Option Grants: Options to purchase 927,000 shares were granted at an exercise price of $4.25 per share.
- Steven Lisi (CEO): 400,000 shares
- Amir Avniel (COO): 250,000 shares
- Erick Lucera (Director): 25,000 shares
- Yoori Lee (Director): 25,000 shares
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, management commentary on future performance, or a discussion of risks and contingencies beyond the standard disclosures regarding the equity plan and the non-filing status of the press release. The Company is identified as an emerging growth company.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2018 financial figures (revenue, net loss, cash position) as they are not included in the 8-K text.
- Verify the vesting schedules for the newly granted options, noting the immediate 25% vesting for executives versus the delayed start for directors.
- Confirm the impact of the new Equity Incentive Plan on potential future dilution (1.5 million share pool).
- Assess the strategic fit of the new board member, Dr. Forbes, given his background in gastrointestinal diseases and clinical development.